C88.40
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission
Clinical Classification Guidelines
Inclusion Terms
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] NOS
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] with failed remission
- Lymphoma of bronchial-associated lymphoid tissue [BALT-lymphoma] NOS
- Lymphoma of bronchial-associated lymphoid tissue [BALT-lymphoma] not having achieved remission
- Lymphoma of bronchial-associated lymphoid tissue [BALT-lymphoma] with failed remission
- Lymphoma of skin-associated lymphoid tissue [SALT-lymphoma] NOS
- Lymphoma of skin-associated lymphoid tissue [SALT-lymphoma] not having achieved remission
- Lymphoma of skin-associated lymphoid tissue [SALT-lymphoma] with failed remission
Medical Intelligence & Overview
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, commonly known as MALT lymphoma, is a type of slow-growing cancer that originates in the lymphoid tissues located outside of the lymph nodes. It can occur in various organs such as the stomach, lungs, skin, and others. When this lymphoma does not respond to initial treatments, it is described as 'not having achieved remission,' indicating that cancerous cells are still present. This guide aims to provide an overview of this condition, its causes, symptoms, diagnosis, and treatment options.
Causes & Symptoms
Clinical Causes: Chronic inflammation or infection, such as Helicobacter pylori in gastric MALT lymphoma Autoimmune diseases like Sjögren's syndrome or Hashimoto's thyroiditis Environmental factors or exposure to certain chemicals Genetic predispositions or mutations occurring in B-cells Underlying immune system deficiencies
Key Symptoms: Persistent swelling or a lump in the affected area Unexplained weight loss Fatigue or feeling unusually tired Localized pain or discomfort Skin changes such as patches, swelling, or skin lesions, if skin tissue is involved Breathing difficulties or cough if lungs are affected Persistent or recurrent infections
Diagnostic & Treatment
Diagnosis Path: Diagnosing extranodal MALT lymphoma involves a combination of medical history assessment, physical examination, imaging studies, and tissue sampling. Biopsies are critical, where a small tissue sample from the affected area is examined microscopically to confirm the presence of lymphoma cells. Additional tests like immunohistochemistry, molecular studies, and blood tests may help determine the specific subtype and extent of the disease. Imaging techniques such as CT scans or PET scans help assess whether the lymphoma has spread beyond the initial site.
Treatment Protocols: Treatment options depend on the location and extent of the lymphoma, as well as the patient’s overall health. In many cases, the goal is to control the disease and alleviate symptoms. Common treatments include: - **Radiation therapy:** Targeted high-energy rays to destroy cancer cells in localized areas - **Chemotherapy:** Use of drugs designed to kill or halt the growth of lymphoma cells - **Targeted therapy:** Medications that attack specific molecules involved in cancer growth - **Immunotherapy:** Boosting the patient’s immune system to fight the lymphoma - **Antibiotic therapy:** In gastric MALT lymphoma linked to Helicobacter pylori, antibiotics may eliminate the infection and induce remission When the lymphoma does not respond to initial treatments, options may include more aggressive therapies or participation in clinical trials. Regular follow-up is essential to monitor for any signs of disease progression or recurrence.
Clinical Advice & FAQs
Billing Guidance
Is C88.40 a billable ICD-10 code?
Yes, C88.40 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C88.40?
Clinical documentation must specify the nature of Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference